rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Moncef Slaoui

Director

Company insider

Files Form 4 as: Director, Vaxcyte; Director, Arcturus Therapeutics Holdings; Director, Moderna; Director, Intellia Therapeutics.

In numbers

Trades disclosed
10
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
4
Companies where not an officer
4
First trade
25 Jul 2017
Last trade
22 Jun 2026
Last filed
23 Jun 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
PCVX VaxcyteDirector · Biotechnology · last 22 Jun 20260 buys · 0 sells
ARCT Arcturus Therapeutics HoldingsDirector · Biotechnology · last 5 Jun 20260 buys · 0 sells
MRNA ModernaDirector · Biotechnology · last 29 Apr 20200 buys · 0 sells
NTLA Intellia TherapeuticsDirector · Genomics & Gene Editing · last 25 Jul 20170 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
22 Jun 2026filed 23 Jun 2026PCVX Vaxcyteoption or derivative · BiotechnologySEC FORM 4 Code A—26,061 at $0.00filing
22 Jun 2026filed 23 Jun 2026PCVX Vaxcyteoption or derivative · BiotechnologySEC FORM 4 Code A—26,061 at $0.00filing
5 Jun 2026filed 15 Jun 2026ARCT Arcturus Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
5 Jun 2026filed 15 Jun 2026ARCT Arcturus Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
9 Jun 2025filed 11 Jun 2025ARCT Arcturus Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
19 Jun 2024filed 21 Jun 2024ARCT Arcturus Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—15,000 at $0.00filing
19 Jun 2024filed 21 Jun 2024ARCT Arcturus Therapeutics Holdingsoption or derivative · BiotechnologySEC FORM 4 Code A—14,794 at $0.00filing
29 Apr 2020filed 30 Apr 2020MRNA Modernaoption or derivative · BiotechnologySEC FORM 4 Code A—18,270 at $0.00filing
27 Jun 2019filed 28 Jun 2019MRNA Modernaoption or derivative · BiotechnologySEC FORM 4 Code A—54,660 at $0.00filing
25 Jul 2017filed 25 Jul 2017NTLA Intellia Therapeuticsoption or derivative · Genomics & Gene EditingSEC FORM 4 Code A—38,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Jim WassilEVP, Chief Scientific Ofc, COO · EVP, Chief Scientific Ofc, COO at Vaxcyte, filing Form 4 there in the last year
Elvia CowanSVP, Finance & CAO · SVP, Finance & CAO at Vaxcyte, filing Form 4 there in the last year
Grant PickeringChief Executive Officer · Chief Executive Officer at Vaxcyte, filing Form 4 there in the last year
Harpreet S. DhaliwalChief Technical Ops Officer · Chief Technical Ops Officer at Vaxcyte, filing Form 4 there in the last year
Andrew GuggenhimePresident and CFO · President and CFO at Vaxcyte, filing Form 4 there in the last year